Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:01 2024-04-15 pm EDT			5-day change	1st Jan Change
126.2 ^USD	+0.36%		-0.29%	+15.75%

Apr. 15	Zacks Adjusts Price Target on Merck & Company to $132 From $128	MT
Apr. 11	Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust	CI

MERCK & CO INC : Goldman Sachs remains Neutral

October 29, 2019 at 08:42 am EDT

Goldman Sachs's research confirms his advice and maintains his neutral opinion on the stock.. The target price remains unchanged at USD 89.

Latest news about Merck & Co., Inc.

Zacks Adjusts Price Target on Merck & Company to $132 From $128	Apr. 15	MT
Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust	Apr. 11	CI
Merck & Co Receives a Shareholder Proposal from National Legal and Policy Center	Apr. 11	CI
Merck & Co Receives a Shareholder Proposal from Kenneth Steiner	Apr. 11	CI
Transcript : Merck & Co., Inc. Presents at Ginkgo's Annual Ferment Conference 2024, Apr-11-2024 09:55 AM	Apr. 11
S&P 500 ends slightly higher as markets brace for inflation data, earnings	Apr. 09	RE
Wall St backs down as markets brace for inflation data, earnings	Apr. 09	RE
Moderna Shares Rise Following Positive Results of Head and Neck Cancer Vaccine in Early Study	Apr. 09	MT
Moderna jumps as personalized cancer vaccine shows benefit in early study	Apr. 09	RE
Berenberg Raises Price Target on Merck & Company to $143 From $140, Maintains Buy Rating	Apr. 08	MT
Geneos cancer vaccine shrinks liver tumors in small trial	Apr. 07	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 05	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 04	RE
Merck & Co., Inc. acquired Abceutics, Inc. for approximately $210 million.	Apr. 04	CI
Merck Starts Phase 3 Clinical Trial of Potential Lung Cancer Combination Therapy	Apr. 04	MT
Merck: launches phase III trial in lung cancer	Apr. 04	CF
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer	Apr. 04	CI
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer	Apr. 03	MT
Merck: 1st patient in raludotatug study	Apr. 03	CF
US takes next step in Medicare drug price negotiations with pharma companies	Apr. 02	RE
Robert Davis, Merck CEO: Another obesity drug?	Mar. 28	MT
Merck: new indication approved for Keytruda in Europe	Mar. 28	CF
Merck Says Keytruda Plus Chemotherapy as Neoadjuvant Treatment Receives Approval From European Commission	Mar. 28	MT
European Commission Approves Merck?s Keytruda® (Pembrolizumab) Plus Chemotherapy	Mar. 28	CI
Alliance Defending Freedom Files Exempt Solicitation Statement with Securities and Exchange Commission	Mar. 28	CI

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Merck & Co., Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

126.2 USD

Average target price

137.2 USD

Spread / Average Target

+8.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MERCK & CO., INC.	+15.75%	320B
ELI LILLY AND COMPANY	+28.79%	676B
NOVO NORDISK A/S	+23.92%	559B
JOHNSON & JOHNSON	-5.84%	356B
ABBVIE INC.	+4.32%	286B
ASTRAZENECA PLC	+3.17%	213B
NOVARTIS AG	+0.11%	207B
ROCHE HOLDING AG	-9.08%	199B
PFIZER, INC.	-10.00%	147B
AMGEN INC.	-7.82%	142B

Other Pharmaceuticals

Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

MERCK & CO INC : Goldman Sachs remains Neutral

Latest news about Merck & Co., Inc.

Chart Merck & Co., Inc.

Company Profile

Income Statement Evolution

Ratings for Merck & Co., Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals